Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL202 in Advanced NSCLC and Breast Cancer
NCT05653752Phase 1Active, not recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of YL202 in non-small cell lung cancer (NSCLC) and breast cancer, sponsored by MediLink Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 21 days and Adverse Events at 36 months. Started Dec 2022; status: active, not recruiting.
02
Drugs
YL202
03
Conditions
non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT05653752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653752.